Go to deals
Healthcare

Mosaic Laboratories has been acquired by Caprion HistoGeneX

The shareholders of Mosaic Laboratories have sold the company to Caprion HistoGeneX.

Founded in 2005 by Lisa Dauffenbach and Chris Kerfoot, Mosaic Laboratories is a Lake Forest, California-based leading provider of bio-analytical testing services supporting translational, preclinical and clinical trial studies for a marquee roster of biotech and pharmaceutical clients globally. Mosaic pioneered proprietary multiplex immunohistochemistry (IHC) services that provide a superior ability to evaluate multiple biomarkers in a single tissue section, and has built a reputation among pharmaceutical companies to produce the most vivid IHC biomarker images. Mosaic supports the most rigorous clinical trial programs in the world, thereby impacting the future of patient therapies for cancer and other diseases.

Caprion HistoGeneX is a provider of proteomics and immune monitoring services for the pharmaceutical and biotechnology industry. The company operates two proprietary immune monitoring platforms that offer multiparametric flow cytometry services for functional analyses of innate and adaptive immune responses while its proteomics business unit, as well as gel-free, label-free mass spectrometry (MS), provide comprehensive, quantitative and robust comparative measurement of proteins across large sets of biological samples for the discovery and validation of protein biomarkers.

Oaklins’ team in Los Angeles acted as advisor to the seller in this transaction.

Service
M&A sell-side
Parties

Talk to the deal team

 Adam  Abramowitz

Adam Abramowitz

Managing Director

Los Angeles, United States
Oaklins Intrepid
 Jonathan  Bluth

Jonathan Bluth

Managing Director

Los Angeles, United States
Oaklins Intrepid

Related deals

ScreenPoint Medical has raised US$28 million in a Series C investment round led by Insight Partners
Healthcare | TMT

ScreenPoint Medical has raised US$28 million in a Series C investment round led by Insight Partners

Netherlands-based ScreenPoint Medical, an AI technology company that develops advanced image recognition and machine learning software to improve early detection of breast cancer, has raised US$28 million (€24 million) in a Series C funding round led by New York-based global venture capital and private equity firm Insight Partners to further develop its technology and accelerate commercial growth of the company’s Transpara AI breast care software.

Learn more
Poolbeg Pharma has completed an Initial Public Offering on AIM
Healthcare

Poolbeg Pharma has completed an Initial Public Offering on AIM

Poolbeg Pharma Plc has raised funds to develop the company.

Learn more
Kungshusen Medicinska has been acquired by Diploma
Healthcare

Kungshusen Medicinska has been acquired by Diploma

Kungshusen Medicinska AB has been acquired by Diploma PLC. Through the acquisition, Diploma gains access to a unique platform for the distribution of medtech products in Sweden.

Learn more